K
Kenichi Shimada
Researcher at Cedars-Sinai Medical Center
Publications - 133
Citations - 12015
Kenichi Shimada is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Inflammasome & Inflammation. The author has an hindex of 38, co-authored 121 publications receiving 8040 citations. Previous affiliations of Kenichi Shimada include Kitasato University & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Regulation of Ferroptotic Cancer Cell Death by GPX4
Wan Seok Yang,Rohitha SriRamaratnam,Matthew Welsch,Kenichi Shimada,Rachid Skouta,Vasanthi S. Viswanathan,Vasanthi S. Viswanathan,Jaime H. Cheah,Paul A. Clemons,Alykhan F. Shamji,Clary B. Clish,Lewis M. Brown,Albert W. Girotti,Virginia W. Cornish,Stuart L. Schreiber,Brent R. Stockwell +15 more
TL;DR: Targeted metabolomic profiling and chemoproteomics revealed that GPX4 is an essential regulator of ferroptotic cancer cell death and sensitivity profiling in 177 cancer cell lines revealed that diffuse large B cell lymphomas and renal cell carcinomas are particularly susceptible to GPx4-regulated ferroPTosis.
Journal ArticleDOI
Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during Apoptosis
Kenichi Shimada,Timothy R. Crother,Justin Karlin,Jargalsaikhan Dagvadorj,Norika Chiba,Shuang Chen,V. Krishnan Ramanujan,Andrea J. Wolf,Laurent Vergnes,David M. Ojcius,Altan Rentsendorj,Mario Vargas,Candace R. Guerrero,Yinsheng Wang,Katherine A. Fitzgerald,David M. Underhill,Terrence Town,Moshe Arditi +17 more
TL;DR: The data reveal that oxidized mtDNA released during programmed cell death causes activation of the NLRP3 inflammasome, and provides a missing link between apoptosis and inflammaome activation, via binding of cytosolic oxidizedmtDNA to the NL RP3 infammasome.
Journal ArticleDOI
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Vasanthi S. Viswanathan,Matthew J. Ryan,Harshil Dhruv,Shubhroz Gill,Ossia M. Eichhoff,Brinton Seashore-Ludlow,Samuel D. Kaffenberger,John K. Eaton,Kenichi Shimada,Andrew J. Aguirre,Andrew J. Aguirre,Srinivas R. Viswanathan,Srinivas R. Viswanathan,Shrikanta Chattopadhyay,Pablo Tamayo,Pablo Tamayo,Wan Seok Yang,Matthew G. Rees,Sixun Chen,Zarko V. Boskovic,Sarah Javaid,Cherrie Huang,Xiaoyun Wu,Yuen-Yi Tseng,Elisabeth Roider,Dong Gao,James M. Cleary,Brian M. Wolpin,Jill P. Mesirov,Jill P. Mesirov,Daniel A. Haber,Daniel A. Haber,Jeffrey A. Engelman,Jesse S. Boehm,Joanne Kotz,Cindy S. Hon,Yu Chen,William C. Hahn,William C. Hahn,Mitchell P. Levesque,John G. Doench,Michael E. Berens,Alykhan F. Shamji,Paul A. Clemons,Brent R. Stockwell,Stuart L. Schreiber,Stuart L. Schreiber,Stuart L. Schreiber +47 more
TL;DR: Vulnerability to ferroptic cell death induced by inhibition of a lipid peroxidase pathway as a feature of therapy-resistant cancer cells across diverse mesenchymal cell-state contexts is identified.
Journal ArticleDOI
Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models.
Rachid Skouta,Scott J. Dixon,Jianlin Wang,Denise E. Dunn,Marina Orman,Kenichi Shimada,Paul A. Rosenberg,Donald C. Lo,Joel M. Weinberg,Andreas Linkermann,Brent R. Stockwell +10 more
TL;DR: A mechanistic model to explain the activity of Fer-1 was developed, which guided the development of ferrostatins with improved properties, and that lipid peroxidation mediates diverse disease phenotypes are suggested.
Journal ArticleDOI
Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis
Kenichi Shimada,Rachid Skouta,Anna Kaplan,Wan Seok Yang,Miki Hayano,Scott J. Dixon,Lewis M. Brown,Carlos A. Valenzuela,Adam J. Wolpaw,Brent R. Stockwell +9 more
TL;DR: Of 56 caspase-independent lethal compounds, modulatory profiling revealed ten inducing three types of regulated non-apoptotic cell death, and lead optimization of one of the ten resulted in the discovery of FIN56, a specific inducer of ferroptosis.